Advertisement

Topics

Companies Related to "Phase studies with filgotinib small bowel fistulizing Crohn" [Most Relevant Company Matches] - Page: 4 RSS

04:20 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "Phase studies with filgotinib small bowel fistulizing Crohn" found in our extensive corporate database of over 50,000 company records.

Showing "Phase studies with filgotinib small bowel fistulizing Crohn" Companies 76–100 of 3,400+

Relevant

TxCell

TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. It is developing innovative personalized cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of autolo...


Biotie Therapies

Biotie Therapies is a drug development biotechnology company with a focus on dependence disorders, inflammatory diseases and thrombosis.The most advanced drugs in development are nalmefene for alcoholism (phase III) and impulse control disorders (phase II), monoclonal VAP-1 antibody and small molecule VAP-1 SSAO enzyme inhibitor for inflammatory diseases (late preclinical), and recombinant biohepa...

Forest Laboratories, Inc. & Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a gro...


AEROVANCE, INC

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing biotherapeutics. The company maintains a solid intellectual property position with its strong portfolio of potential breakthrough products now in clinical development and several pre-clinical programs. The lead products are human recombinant proteins: AEROVANT™, an IL-4 and IL-13 recepto...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

KuDOS Pharmaceuticals Limited

KuDOS Pharmaceuticals is a leader in the discovery and development of novel small molecule drugs that target DNA repair and related systems for the treatment f human diseases, in particular cancer. The company was founded by Professor Stephen Jackson of the Wellcome/Cancer Research UK Institute of the University of Cambridge, UK, an internationally renowned scientist in the field of DNA repair.Th...

Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is dedicated to alleviating the burden of patients suffering from autoimmune diseases by developing novel immunotherapeutic agents. Immune's lead product candidate, bertilimumab, is in Phase 2 clinical development for bullous pemphigoid, an orphan autoimmune dermatological condition, and for ulcerative colitis. Oth...

Novum Pharmaceutical Research Services

For over 25 years, Novum has been a world leader in the conduct of clinical trials and equivalency studies. We have completed over 2,000 studies with over 36,000 participants for more than 200 pharmaceutical companies. In the past year, we have paid over $3.3 million to individuals who have done studies.There are three locations from which you can participate in studies - Pittsburgh, PA; Houston, ...

Specials Laboratory Ltd

Based in Northumberland, our award-winning company reliably makes and delivers unlicensed medicines (Specials) to thousands of community and hospital Pharmacists and Doctors throughout the UK and Ireland - usually within 24 hours of an order being placed. We also supply ‘Special Obtain’ items to help pharmacists when they require a product that is not a regular line and therefore not...

California Clinical Trials

Since 1981 California Clinical Trials (CCT) has been at the forefront of drug development. Our best-in-class clinical experts, research staff, and trained physicians all work together seamlessly to bring hope to patients around the world. Our executive team comprises outstanding leaders in medical science. Whether you need careful patient selection for your Phase 1 studies, or experience in drug d...

Tarsa Therapeutics, Inc.

Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that inhibits bone resorption, the process underlying osteoporosis. Availability of an oral formulation is expected to generate wider use of this established osteoporosis treatment, which currently is available only in injectable and intranasal formulations. Tarsa's oral calcit...

Biothera, the Immune Health Company

Biothera is a privately held biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer. Its lead cancer drug Imprime PGG is currently in multiple Phase 2 clinical trials for non-small cell lung and in a Phase 3 for colorectal cancer. (www.biothera.com)

Harrison Clinical Research Limited

Since 1987, we have established offices in the UK (1992), Benelux (1996), Israel (1998), Spain and France (2000), Italy (2002), Austria, serving Eastern Europe (2004) as well as in Russia, Ukraine, Poland (2007) and USA (HCRAmerica, 2008). All our offices offer complete monitoring of clinical studies from Phase II-IV and local consultancy. Over the years our Munich headquarters has expanded and h...

Arcus Biosciences

Arcus Biosciences (“Arcus”) is a biotechnology company focused on the discovery and development of innovative cancer immunotherapies. Arcus was founded in 2015 by Terry Rosen and Juan Jaen, the co-founders of Flexus Biosciences, which in February 2015 was acquired by Bristol-Myers Squibb to access Flexus’s IDO inhibitor, which was in preclinical...

PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees ...

Prosidion Ltd

(OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Ph...

TGA Sciences, Inc

TGA Sciences, Inc. is a contract research laboratory providing the Pharmaceutical, Biotechnology and Research communities a comprehensive range of laboratory services in support of research and clinical studies. We offer the client a complete package of customized testing systems utilized in pre-clinical through Phase IV studies, all in compliance with cGLP and cGMP requirements. We specialize, an...

Progenity Inc.

Progenity is a biotechnology company with a market-leading presence in Women’s Health molecular testing and a pipeline of proprietary tests and therapeutic applications under development. Progenity has a portfolio of innovative technologies and tests for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and noninvasive ...

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can l...

FSD Pharma Inc. FSD Pharma Inc.

FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company’s phase one growth plan involves the development ...

Harrison Clinical Research

Since 1987, we have established affiliate offices in the UK (1992), Benelux (1996), Israel (1998), Spain and France (2000), Italy (2002), Austria, serving Eastern Europe (2004) as well as in Russia, Ukraine and Poland (2007) and we have representative offices in Japan and USA. All our affiliate offices offer complate monitoring of clinical studies from Phase II-IV and local consultancy. Over the...

TorreyPines Therapeutics

We are a clinical stage biopharmaceutical company committed to discovering, developing and commercializing novel small molecules to treat diseases and disorders of the central nervous system (CNS). Our initial focus is on delivering potentially next generation therapies for chronic pain, including migraine, and cognitive disorders such as cognitive impairment associated with schizophrenia (CIAS) a...

Radius

RAD1901 is a potential first-in-class novel selective estrogen receptor modulator (SERM) under development at Radius for menopausal hot flashes. SERMs are small molecules that bind to and selectively modulate estrogen receptors. These molecules have the ability to stimulate or block estrogen's activity in different types of tissue, functioning as estrogen receptor agonists in some tissues and as e...

Cyclacel Limited

Cyclacel Limited (Dundee, UK) uses cell cycle control biology and state-of-the-art rational drug design chemistry to develop novel cancer therapeutics including small molecule CDK inhibitors (CYC200; CYC400), Penetratin®-small molecule complexes (CYC300), Pimetic™ small molecules mimicking natural cancer suppressing genes (CYC100), and intelligent delivery and targeting systems (Penetratin® an...

FortuneRock (China) Co., Ltd.

FortuneRock (China) Co., Ltd., a biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombinant protein drugs with h...


More From BioPortfolio on "Phase studies with filgotinib small bowel fistulizing Crohn"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks